Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abstract, ACC, adequacy, Aerpio, Alert, arm, ARVO, ballot, benchmark, biosimilar, boost, Burn, CALM, Carl, Circuit, cited, CJEU, cloud, colloquially, commentary, Commerce, Commissioner, conflict, CPPA, CPRA, CPT, CST, curb, database, DAVIO, deceptive, democratic, destination, discarded, domain, double, downstream, EDPB, embody, EUR, explicit, faricimab, FDPIC, foveal, franchise, FY, grew, HR, ID, Intelligence, intermittent, Isabelle, Israel, John, Journal, Lefebvre, living, LUMINA, MD, median, Michael, migration, mix, moment, mono, NMPA, OAI, OIG, Omicron, organizational, pace, paper, paydown, phosphatase, phosphate, Pine, poster, prime, problem, propensity, readout, reborrowed, Regillo, regime, Republic, resumed, revolving, rewritten, Russell, Shield, software, speaker, spectral, stable, Subspecialty, Subtopic, succeeding, susvimo, symposium, SYNCRONICITY, Terminology, text, thereon, Turkey, ug, unavoidable, uncomfortable, uncontrolled, unfair, untreated, unutilized, upheld, VABYSMO, vacate, variant, Venezuela, video, Weet, withdrawn
Removed:
assuming, ceasing, closed, conjunctiva, daily, disposal, drawdown, floor, function, Genentech, gradually, hemorrhage, humor, hypertension, layer, leaky, lessee, LIBOR, licensee, miniaturized, perfected, placebo, plana, portal, ratably, reclassified, redeemed, refill, refillable, refilled, remeasured, representing, reservoir, reverse, sclera, shared, simultaneously, supporting, validation, vasculature
Filing tables
Filing exhibits
Related press release
Associated EYPT transcripts
EYPT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-152146, 333-163208, 333-216166, 333-227525, 333-233137, 333-249902, and 333-258595 on Form S-8 and Registration Nos. 333-226341, 333-253053, 333-252170, and 333-258598 on Form S-3 of our report dated March 11, 2022, relating to the financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries appearing in this Annual Report on Form 10-K for the year ended December 31, 2021.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 11, 2022